Skip to main content

Table 1 Patients' and tumor characteristics

From: Comparison of definite chemoradiation therapy with carboplatin/paclitaxel or cisplatin/5-fluoruracil in patients with squamous cell carcinoma of the esophagus

Parameter

Intention to treat analysis

Per protocol analysis

Carb/TAX

n = 22

CDDP/5FU

n = 25

p-value

Carb/TAX

n = 18

CDDP/5FU

n = 23

p-value

Median Age

(IQR)

68

(62–74)

66

(62–69)

0.149

68

(62–72)

66

(58–69)

0.337

Male

15 (68%)

21 (84%)

0.303

13 (72%)

19 (83%)

0.471

T-stage

0.247

  

0.265

 uT1

1 (5%)

0 (0%)

 

1 (6%)

0 (0%)

 

 uT2

4 (18%)

2 (8%)

 

4 (22%)

2 (9%)

 

 uT3

16 (73%)

27 (72%)

 

12 (67%)

17 (74%)

 

 uT4

1 (5%)

5 (20%)

 

1 (6%)

4 (17%)

 

uN+

21 (95%)

23 (92%)

1.000

17 (94%)

21 (91%)

1.000

cM0

22 (100%)

24 (96%)

1.000

18 (100%)

22 (96%)

1.000

Grading

0.756

  

0.515

 G2

11 (61%)

13 (52%)

 

9 (64%)

12 (52%)

 

 G3

7 (39%)

12 (48%)

 

5 (36%)

11 (48%)

 

Median tumor extension (cm)

(IQR)

5

(3–7)

5

(5–7)

0.216

5

(3–6)

5

(5–6)

0.108

Median radiation dose (Gy)

(IQR)

59.4

(55.8–59.4)

54.0

(54.0–54.0)

< 0.001

59.4

(54.0–59.4)

54.0

(54.0–54.0)

< 0.001

Median daily radiation dose (Gy)

(IQR)

1.8

(1.8–1.8)

1.8

(1.8–1.8)

0.253

1.8

(1.8–1.8)

1.8

(1.8–2.0)

0.429

  1. 5-FU 5-fluoruracil, IQR inter-quartiles-range, Gy gray